TREM2 and Alzheimer disease: Repeated administration of a TREM2 agonist antibody (AL002) increased plaque-associated microglia and reduced amyloid deposition in 5× FAD mice, including those expressing both the common variant and the R47H variant of human TREM2 (Wang et al., 2020a), and has progressed to phase 2 trials for early AD (NCT04592874).